Evan Y. Yu
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (19)
Year:
2026
Year:
2026
Year:
2026
Patients with prostate cancer and homologous recombination repair alterations face worse outcomes. Early use of PARP inhibitors, especially in BRCA-mutated cancers, is promising. However, optimal timing, sequencing, and benefits for non-BRCA alterations remain unclear, underscoring the need for well-designed clinical trials and personalized treatment discussions. See related article by Hage Chehade et al., p. 4101
Year:
2025
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature, and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and 2 (online only) for more . PURPOSE To evaluate evidence on germline and somatic genomic testing for patients with metastatic prostate cancer and provide recommendations. METHODS A systematic review by a multidisciplinary panel with patient representation was conducted. The PubMed database was searched from January 2018 to May 2024. Articles were selected for inclusion if they reported on patients with metastatic prostate cancer who received a germline or somatic genomic test and/or made comparisons between those tests, reported detection rates, prognostic information, or treatment implications. RESULTS A total of 1,713 papers were identified in the literature search. After applying the eligibility criteria, 14 remained: eight systematic reviews and six clinical trials. RECOMMENDATIONS Patients with metastatic prostate cancer should undergo both germline and somatic DNA sequencing using panel-based assays. These tests can guide the use of poly(ADP-ribose) polymerase inhibitors, which have a survival benefit in metastatic castration-resistant prostate cancer. In addition, germline testing may have screening implications for additional cancers for patients and cascade testing implications for family members. The data supporting when to perform repeat testing and optimal tissue type to use (eg, primary tumor v metastatic biopsy versus circulating tumor DNA [ctDNA] testing) are more limited, but this panel recommends considering retesting in patients whose results were previously negative or uninformative, and to consider either a metastatic biopsy or ctDNA when a significant change in clinical status occurs. Next-generation genomic sequencing findings that are associated with prognostic only (and not predictive) value should not be used to guide treatment outside of a clinical trial. Additional information is available at www.asco.org/genitourinary-cancer-guidelines .
Year:
2025
Human kallikrein (KLK) 2 is a prostate cancer tissue–specific protein that is regulated by androgen receptor signaling. KLK2 was not previously recognized as a therapeutic target as it was shown to be a secreted serine protease with no evidence for localization to the cell surface. It has now been demonstrated that KLK2 is expressed on the cell surface and is targetable by various methodologies. See related article by Shen et al., p. 4543
Year:
2025
Year:
2025
A and B, Representative micrographs of HER2 IHC staining in prostate cancer ( A ) and urothelial cancer ( B ) autopsy specimens. C, Number of patients with at least one tumor with the indicated HER2 IHC score, color coded by cancer type. D, Number of tumors across all patients with the indicated HER2 IHC score, color coded by cancer type. E and F, Percent of tumors expressing the indicated level of HER2 staining by IHC according to the tumor site sampled in prostate ( E ) and urothelial ( F ) cancer cohorts. Anatomic sites with only one representative tumor were excluded. PC, prostate cancer; UC, urothelial carcinoma.
Year:
2025
A and B, Box plots indicating the relationship between HER2 score with protein expression of key cell surface antigens as measured by IHC in ( A ) prostate cancer and ( B ) urothelial cancer.
Year:
2025
HER2 is an oncogenic driver in multiple cancers and a predictive biomarker for HER2-targeted therapies. Although HER2-directed therapies like fam-trastuzumab deruxtecan are approved for HER2-positive breast and other solid tumors, the landscape of HER2 expression in advanced prostate cancer and urothelial carcinoma remains inadequately characterized. We evaluated HER2 protein expression in metastatic prostate cancer and urothelial carcinoma using a validated IHC assay on tissue microarrays constructed from the University of Washington Tissue Acquisition Necropsy Program. HER2 expression was scored using standardized gastric cancer criteria. Genomic analysis of ERBB2 alterations was conducted on a subset of samples. HER2 expression heterogeneity and its relationship with other surface markers were also evaluated. In the prostate cancer cohort ( n = 52 patients, 1–19 tumors per patient), HER2 expression was low, with no 3+ expression observed and only five (10%) patients exhibiting 2+ expression. Low-level ERBB2 copy-number gains were observed in some tumors but did not correlate with HER2 protein expression ( P = 0.2). In urothelial carcinoma ( n = 20, 2–6 tumors per patient), HER2 expression was more frequent, with ≥2+ expression observed in six (30%) cases and 3+ expression observed in three (15%) cases in at least one tumor. Urothelial carcinoma samples showed less heterogeneity, with more consistent expression across metastases. HER2 overexpression is rare and heterogeneous in metastatic prostate cancer, limiting its utility as a therapeutic target. HER2 expression is more prevalent and uniform in urothelial carcinoma. These findings underscore the importance of comprehensive HER2 assessment in advanced urothelial carcinoma and suggest that success of HER2-directed therapies in prostate cancer will require careful case selection. Significance: This study demonstrates that HER2 is rarely overexpressed in metastatic prostate cancer but is more common and consistent in urothelial carcinoma. These findings highlight the need for HER2 testing in urothelial cancer and suggest that HER2-targeted therapies in prostate cancer will require careful patient selection.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (45)
Andrew Armstrong
Professor
Duke Cancer Institute
Guru P. Sonpavde
University of Central Florida
Anja Williams
Scripps Research Institute
Gwenaelle Gravis
Praticien Hospitalier Spécialiste Oncologie; Head of the onco-urology (since 2001) , Head of the outpatient unit (2002-2018) , Reviewer for the Clinical Research protocol (since 2017)
Institut Paoli-Calmettes
Hyun Jung Lee
Assistant Professor
Pusan National University Yangsan Hospital
Laura Graham
Assistant Professor
University of Colorado Boulder
Thomas Powles
Professor of Genitourinary Oncology
Queen Mary University of London
Andrew C. Hsieh
Fred Hutchinson Cancer Research Center
Yves Fradet
Full professor
Laval University
Victor Moreno
Director
Hospital Universitario Fundación Jiménez Díaz
Christof Vulsteke
University of Antwerp
Alicia Morgans
Dana-Farber Cancer Institute
Elad Sharon
Associate Professor
Harvard University
Lawrence True
Professor
University of Washington
Ronac Mamtani
University of Pennsylvania
Gavin Ha
Associate Professor
Fred Hutchinson Cancer Research Center
Olivier Huillard
Université Paris-Saclay
Michael Haffner
Fred Hutchinson Cancer Research Center
Elisabeth I. Heath
Wayne State University School of Medicine
Stéphane Oudard
Université Paris-Saclay
Sonali Arora
Fred Hutchinson Cancer Research Center
Heather H. Cheng
Professor
University of Washington
Leonard Appleman
Associate Professor
University of Pittsburgh
Petros Grivas
University of Washington
Radhika A Patel
Fred Hutch Cancer Center
Declan Murphy
sir peter maccallum department of oncology university of melbourne melbourne victoria australia
Leonard D'Amico
Staff Scientist
Fred Hutchinson Cancer Research Center
Colm Morrissey
Research Professor
University of Washington
Yohann Loriot
Institut Gustave Roussy
Sebastian Ochsenreither
Charité - Universitätsmedizin Berlin
Michael T. Schweizer
University of Washington
Matthew D. Galsky
Radboud University Medical Center
Sara Hurvitz
Professor, Division Head
Washington University School of Medicine
Bruce Montgomery
University of Washington
Russell Z. Szmulewitz
Associate Professor
University of Chicago
Peter S. Nelson
Fred Hutchinson Cancer Research Center
Russell K. Pachynski
Washington University School of Medicine
JEREMIE CALAIS
Professor
David Geffen School of Medicine at UCLA
Neeraj Agarwal
Faculty Member
Dana-Farber Cancer Institute
Maria Tretiakova
Professor
University of Washington
Daniel P. Petrylak
-
Gennady Bratslavsky
Professor & Chair
SUNY Upstate Medical University
Miguel Martin
Universidad Complutense de Madrid
Jessica Hawley
Assistant Professor
University of Washington
Sebastien Hotte
McMaster University
Make your next move.
Prepare your application
Review drafts before you send them.